RIGL Strangle Strategy
RIGL (Rigel Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates.
RIGL (Rigel Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $594.5M, a trailing P/E of 1.62, a beta of 1.20 versus the broader market, a 52-week range of 18.13-52.24, average daily share volume of 383K, a public-listing history dating back to 2000, approximately 162 full-time employees. These structural characteristics shape how RIGL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.20 places RIGL roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline. The trailing P/E of 1.62 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price.
What is a strangle on RIGL?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current RIGL snapshot
As of May 15, 2026, spot at $29.16, ATM IV 59.80%, IV rank 12.44%, expected move 17.14%. The strangle on RIGL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on RIGL specifically: RIGL IV at 59.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a RIGL strangle, with a market-implied 1-standard-deviation move of approximately 17.14% (roughly $5.00 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RIGL expiries trade a higher absolute premium for lower per-day decay. Position sizing on RIGL should anchor to the underlying notional of $29.16 per share and to the trader's directional view on RIGL stock.
RIGL strangle setup
The RIGL strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RIGL near $29.16, the first option leg uses a $31.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RIGL chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RIGL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $31.00 | $1.53 |
| Buy 1 | Put | $28.00 | $1.05 |
RIGL strangle risk and reward
- Net Premium / Debit
- -$257.50
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$257.50
- Breakeven(s)
- $25.43, $33.58
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
RIGL strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on RIGL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$2,541.50 |
| $6.46 | -77.9% | +$1,896.87 |
| $12.90 | -55.8% | +$1,252.23 |
| $19.35 | -33.6% | +$607.60 |
| $25.80 | -11.5% | -$37.03 |
| $32.24 | +10.6% | -$133.33 |
| $38.69 | +32.7% | +$511.30 |
| $45.13 | +54.8% | +$1,155.93 |
| $51.58 | +76.9% | +$1,800.57 |
| $58.03 | +99.0% | +$2,445.20 |
When traders use strangle on RIGL
Strangles on RIGL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the RIGL chain.
RIGL thesis for this strangle
The market-implied 1-standard-deviation range for RIGL extends from approximately $24.16 on the downside to $34.16 on the upside. A RIGL long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current RIGL IV rank near 12.44% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on RIGL at 59.80%. As a Healthcare name, RIGL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RIGL-specific events.
RIGL strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RIGL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RIGL alongside the broader basket even when RIGL-specific fundamentals are unchanged. Always rebuild the position from current RIGL chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on RIGL?
- A strangle on RIGL is the strangle strategy applied to RIGL (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With RIGL stock trading near $29.16, the strikes shown on this page are snapped to the nearest listed RIGL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are RIGL strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the RIGL strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 59.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$257.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a RIGL strangle?
- The breakeven for the RIGL strangle priced on this page is roughly $25.43 and $33.58 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RIGL market-implied 1-standard-deviation expected move is approximately 17.14%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on RIGL?
- Strangles on RIGL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the RIGL chain.
- How does current RIGL implied volatility affect this strangle?
- RIGL ATM IV is at 59.80% with IV rank near 12.44%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.